Ascendis Pharma A/S (ASND) P/E Ratio History
Deep ValueTrading at -55.4x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Ascendis Pharma A/S (ASND) trades at a price-to-earnings ratio of -55.4x, with a stock price of $230.83 and trailing twelve-month earnings per share of $7.85.
The current P/E is 283% below its 5-year average of 30.3x. Over the past five years, ASND's P/E has ranged from a low of 30.3x to a high of 30.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ASND trades at a 350% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, ASND trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ASND DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ASND Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ASND P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $20B | 15.3 | -Best | +4173%Best | |
| $7B | 31.5 | -Best | -34% | |
| $4B | 9.4Lowest | -Best | +68% | |
| $10B | 50.9 | -Best | +128% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ASND Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $228.73 | $7.55 | 30.3x | +0% |
Average P/E for displayed period: 30.3x
Full Stock Analysis
Deep dive into ASND consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ASND — Frequently Asked Questions
Quick answers to the most common questions about buying ASND stock.
What is ASND's P/E ratio?
Ascendis Pharma A/S (ASND) trailing twelve-month P/E ratio is -55.4x, based on TTM diluted EPS of $7.85. The 5-year average P/E is 30.3x and the historical range spans 30.3x to 30.3x.
Is ASND stock overvalued or undervalued?
ASND trades at -55.4x P/E, below its 5-year average of 30.3x. At the 0th percentile of its historical range (30.3x–30.3x), the stock is priced at a discount to its own history.
Is ASND stock expensive?
No, ASND is not expensive on a historical basis. The current P/E of -55.4x is below the 5-year average of 30.3x and sits at the 0th percentile of its valuation range.
What is ASND's historical P/E range?
Over the past 5 years, ASND's P/E ratio has ranged from 30.3x to 30.3x, with a median of 30.3x and an average of 30.3x. The current P/E of -55.4x places the stock at the 0th percentile of this range. Full historical data spans 2026–2026.
How does ASND's P/E compare to the S&P 500?
ASND trades at -55.4x P/E versus the S&P 500 median of 24.4x. The 327% discount to the market suggests lower growth expectations or perceived higher risk.
How does ASND's valuation compare to Healthcare peers?
Ascendis Pharma A/S P/E of -55.4x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ASND's PEG ratio?
ASND PEG ratio is N/A, based on a P/E of -55.4x and EPS growth of 44.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ASND's earnings yield?
ASND earnings yield is N/A, the inverse of its -55.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.